Musashi in Cancer

Musashi in Cancer

Related Publications

Erazo, T., Evans, C. M., Zakheim, D., Chu, K. L., Refermat, A. Y., Asgari, Z., Yang, X., Da Silva Ferreira, M., Mehta, S., Russo, M. V., Knezevic, A., Zhang, X. P., Chen, Z., Fennell, M., Garippa, R., Seshan, V., de Stanchina, E., Barbash, O., Batlevi, C. L., Leslie, C. S., … Kharas, M. G. 2022. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Nature communications, 13(1), 5676.

[ PubMed ]

Jiang, L., Xue, S., Xu, J., Fu, X., Wei, J., & Zhang, C. 2022. Prognostic value of Musashi 2 (MSI2) in cancer patients: A systematic review and meta-analysis. Frontiers in oncology, 12, 969632.

[ PubMed ]

Chen, H. Y., Wang, M. L., Laurent, B., Hsu, C. H., Chen, M. T., Lin, L. T., Shen, J., Chang, W. C., Hsu, J., Hung, M. C., Chen, Y. W., Huang, P. I., Yang, Y. P., Li, C. P., Ma, H. I., Chen, C. H., Lin, W. C., & Chiou, S. H. 2020. Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. Theranostics, 10(1), 201–217.

[ PubMed ]

Kharas MG, Lengner CJ. 2017. Stem Cells, Cancer, and MUSASHI in Blood and Guts. Trends Cancer 3(5):347-356

[ PubMed ]

Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, Koechlein CS, Zimdahl B, Yano M, Kopp J, Kritzik M, Sicklick J, Sander M, Grandgenett PM, Hollingsworth MA, Shibata S, Pizzo D, Valasek M, Sasik R, Scadeng M, Okano H, Kim Y, MacLeod AR, Lowy AM, Reya T. 2016. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature. 534(7607):407-411

 

Fox RG, Park FD, Koechlein CS, Kritzik M, Reya T. 2015. Musashi signaling in stem cells and cancer. Annu Rev Cell Dev Biol. 31:249-67

[ PubMed ]

Vo DT, Subramaniam D, Remke M, Burton TL, Uren PJ, Gelfond JA, de Sousa Abreu R, Burns SC, Qiao M, Suresh U, Korshunov A, Dubuc AM, Northcott PA, Smith AD, Pfister SM, Taylor MD, Janga SC, Anant S, Vogel C, Penalva LO. 2012. The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. Am J Pathol. 181(5):1762-72

[ PubMed ]

Wang XY, Penalva LO, Yuan H, Linnoila RI, Lu J, Okano H, Glazer RI. 2010. Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer 9:221

[ PubMed ]

Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T. 2010. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466(7307):765–68

[ PubMed ]

Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Fröhling S, Fleming M, Eber BL, Gilliland DG, Jaenisch R, Daley GQ. 2010. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat. Med. 16(8):903–8

[ PubMed ]

Sureban SM, May R, George RJ, Dieckgraefe BK, McLeod HL, Ramalingam S, Bishnupuri KS, Natarajan G, Anant S, Houchen CW. 2008. Knockdown of RNA binding protein Musashi-1 leads to tumor regression in vivo. Gastroenterology 134(5):1448–58
PubMed

[ PubMed ]

Barbouti A, Höglund M, Johansson B, Lassen C, Nilsson PG, Hagemeijer A, Mitelman F, Fioretos T. 2003. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23). Cancer Res. 63(6):1202–6

[ PubMed ]

Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. 2003. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 100(25):15178-83.

[ PubMed ]